Revolution Medicines, Inc. Common Stock (RVMD) Valuation
Historical valuation analysis based on 500 data points (2024-09-27 to 2026-09-25)
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabiliti...
Revolution Medicines, Inc. Common Stock (RVMD) currently trades at a P/S ratio of 202.03 (range: 201.10–283.60, 2th percentile — cheap relative to its history).
Revolution Medicines, Inc. Common Stock trades well below its historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/S Ratio | 202.03 | 201.10 | 229.27 | 283.60 | 2th | cheap relative to its history |
Revolution Medicines, Inc. Common Stock (RVMD) Valuation & P/E History
Revolution Medicines, Inc. Common Stock (RVMD) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry currently trading at $207.01 with a market capitalization of $44.4 billion. This page provides historical valuation analysis for RVMD based on 500 data points covering 2024-09-27 to 2026-09-25.. The P/S ratio of 202.03 compares to a median of 229.27.
RVMD Valuation Metrics & Historical Range
The valuation table above shows Revolution Medicines, Inc. Common Stock's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether RVMD is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests RVMD is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Revolution Medicines, Inc. Common Stock.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is RVMD Overvalued or Undervalued?
Revolution Medicines, Inc. Common Stock trades well below its historical valuation range across most metrics. The overall valuation percentile of 2 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive RVMD is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full RVMD analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.RVMD trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.